101 related articles for article (PubMed ID: 9301465)
1. Comments on Adaptation of the Cellscan technique for the SCM test in breast cancer Rahmani et al., Eur. J. Cancer, 32A, no. 10, pp. 1758-1765 1996.
Birindelli S; Colnaghi MI; Pilotti S
Eur J Cancer; 1997 Jul; 33(8):1333-5. PubMed ID: 9301465
[No Abstract] [Full Text] [Related]
2. Adaptation of the cellscan technique for the SCM test in breast cancer.
Rahmani H; Deutsch M; Ron I; Gerbat S; Tirosh R; Weinreb A; Chaitchik S; Lalchuk S
Eur J Cancer; 1996 Sep; 32A(10):1758-65. PubMed ID: 8983287
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte fluorescence polarization measurements with the cellscan system: application to the SCM cancer test.
Deutsch M; Ron I; Weinreb A; Tirosh R; Chaitchik S
Cytometry; 1996 Feb; 23(2):159-65. PubMed ID: 8742175
[TBL] [Abstract][Full Text] [Related]
4. Comments on the Role of reproductive and menstrual factors in cancer of the breast before and after menopause, Talamini et al., Eur J Cancer, 32A, no. 2, pp. 303-310, 1996.
Berstein L
Eur J Cancer; 1996 Nov; 32A(12):2181-2. PubMed ID: 9014764
[No Abstract] [Full Text] [Related]
5. Comments on Inadequacy of iridium implant as sole radiation treatment for operable breast cancer, Fentiman et al., Eur J Cancer 1996, 32A, pp. 608-611.
Dale RG; Jones B; Price P
Eur J Cancer; 1997 Sep; 33(10):1707-8. PubMed ID: 9389938
[No Abstract] [Full Text] [Related]
6. Comments on Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression, Oliver et al., Eur J Cancer, 32A, No. 3, pp. 396-397, 1996.
Mokbel K
Eur J Cancer; 1996 Dec; 32A(13):2364-6. PubMed ID: 9038624
[No Abstract] [Full Text] [Related]
7. A flow system adaptation of the SCM test for detection of lymphocyte response in patients with recurrent breast cancer.
Stewart S; Pritchard KI; Meakin JW; Price GB
Clin Immunol Immunopathol; 1979 Jun; 13(2):171-81. PubMed ID: 156612
[No Abstract] [Full Text] [Related]
8. Comments on Swiss plan to fight against breast cancer, International Cancer News, Eur J Cancer, 32A, no. 11, pp. 1830-1831, 1996.
Weisburger JH
Eur J Cancer; 1997 Jun; 33(7):1156-7. PubMed ID: 9376199
[No Abstract] [Full Text] [Related]
9. Comments on Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute, Bonadonna, Eur J Cancer, 32A, No. 2, pp. 209-214, 1996.
Barişta I
Eur J Cancer; 1997 Jan; 33(1):164-5. PubMed ID: 9071917
[No Abstract] [Full Text] [Related]
10. Comments on Health-related quality of life of adults surviving malignancies in childhood, Apajasalo et al., Eur J Cancer, 32A, No. 8, pp. 1354-1358, 1996.
Barr RD; Furlong W; Feeny D
Eur J Cancer; 1997 Mar; 33(3):506-7. PubMed ID: 9155541
[No Abstract] [Full Text] [Related]
11. Application of a static fluorescence-based cytometer (the CellScan) in basic cytometric studies, clinical pharmacology, oncology and clinical immunology.
Harel M; Gilburd B; Schiffenbauer YS; Shoenfeld Y
Clin Dev Immunol; 2005 Sep; 12(3):187-95. PubMed ID: 16295524
[TBL] [Abstract][Full Text] [Related]
12. Application of a static fluorescence-based cytometer: the CellScan in clinical immunology.
Szyper-Kravitz M; Harel M; Gilburd B; Trubniykov E; Schiffenbauer YS; Shoenfeld Y
Lupus; 2006; 15(7):436-41. PubMed ID: 16898179
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the SCM test for the diagnosis of cancer of the breast.
Chaitchik S; Deutsch M; Asher O; Krauss G; Lebovich P; Michlin H; Weinreb A
Eur J Cancer Clin Oncol; 1988 May; 24(5):861-6. PubMed ID: 3169091
[TBL] [Abstract][Full Text] [Related]
14. Comments on Costs of treating advanced colorectal cancer, Ross et al., Eur J Cancer 1996, 32A, S13-S17.
Benson R; Wilson C; Williams MV
Eur J Cancer; 1998 Mar; 34(4):593-4. PubMed ID: 9713318
[No Abstract] [Full Text] [Related]
15. Validation of the SCM-test for the diagnosis of cancer.
Deutsch M; Weinreb A
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):187-93. PubMed ID: 6681765
[TBL] [Abstract][Full Text] [Related]
16. Comments on Survival of breast cancer patients in Lithuania and Norway, 1988-1992, Kliukiene and Andersen, Eur J Cancer 1998, 34, pp. 372-377.
de Souza RM
Eur J Cancer; 1998 Oct; 34(11):1812-3. PubMed ID: 9893674
[No Abstract] [Full Text] [Related]
17. Height and breast cancer risk--the bias of self-reported versus measured results. Comments on height and breast cancer risk, Tavani et al., Eur J Cancer 1998, 34, 543-547.
Wang DY; Fentiman IS
Eur J Cancer; 1999 Jan; 35(1):162-3. PubMed ID: 10211106
[No Abstract] [Full Text] [Related]
18. Lymphocyte response to antigen stimulation as measured by fluorescence polarization (SCM test).
Pritchard JA; Sutherland WH
Br J Cancer; 1978 Aug; 38(2):339-43. PubMed ID: 698051
[No Abstract] [Full Text] [Related]
19. Comments on: Tagging sentinel lymph nodes: a study of 100 patients with breast cancer. Bobin, et al., Eur J Cancer 1999, 35, 569-573.
Sakorafas GH; Tsiotou AG
Eur J Cancer; 1999 Nov; 35(12):1743. PubMed ID: 10674023
[No Abstract] [Full Text] [Related]
20. Comments on: Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics, Vasen et al., Eur J Cancer 1998, 34, 1922-1926.
Eisinger F; Sobol H
Eur J Cancer; 1999 May; 35(5):859-60. PubMed ID: 10505049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
